Study title: A 7 -Day, Open-Label, Multicenter, Pharmacokinetic study (Part 1) followed by a 7-Day, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study (Part 2) of IV Sildenafil in the treatment of neonates with persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory failure and at risk for PPHN.
| Type of medicine: Centrally authorised medicines | |||||
| Therapeutic area: Cardiovascular Diseases | |||||
| Brands: Please see report, Please see report, Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: sildenafil | |||||
| ATC code: G04BE03 | |||||
| Document link: A1481157 PhRMA Web Synopsis.pdf | |||||
| Document date: 2013-10-01 | |||||
| Study number: A1481157 | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | Y | - | - | - | |